SPK 3006：新薬の洞察と市場予測 (2030年)
SPK 3006 - Emerging Drug Insight and Market Forecast - 2030
|SPK 3006：新薬の洞察と市場予測 (2030年)|
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
SPK 3006はポンペ病を対象とした、現在治験中の肝臓向けAAV遺伝子治療薬です。SPK 3006は肝臓から分泌される修飾酵素を生成するように設計されており、それがGAAの血漿レベルの維持やGAAに対する免疫原性の低下を通じて、筋肉組織への取り込み量を増加させるようになっています。
当レポートでは、ポンペ病の治療薬であるSPK 3006の市場構造・動向について分析し、製品の概要 (用法・容量、作用機序など) や関連規制、製品開発・治験の進行状況、主要7ヶ国 (米国、欧州5ヶ国 (ドイツ、フランス、イタリア、スペイン、英国)、日本) の市場規模の動向見通し (2020～2030年)、市場の競争状態・SWOT分析、他の治療薬との競合状態、資本取引の動き、今後の市場成長の可能性などを調査・考察しております。
"SPK 3006 - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Pompe Disease in 7 Major Markets. A detailed picture of the SPK 3006 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
SPK-3006 is an investigational liver-directed AAV gene therapy for Pompe disease. SPK-3006 has been engineered to produce a modified enzyme that is secreted from the liver, which may sustain GAA plasma levels and lower immunogenicity to GAA to potentially provide greater uptake in muscle tissue. The transgene was in-licensed in 2017 from Genethon, a non-profit research and development organization dedicated to the development of gene therapies for orphan genetic diseases from research to clinical validation. Spark Therapeutics retains global commercialization rights to SPK-3006.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
This report provides a detailed market assessment of SPK 3006 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of SPK 3006 covering trial interventions, trial conditions, trial status, start and completion dates.